SCRN2

Across TCGA pan-cancer cohorts, SCRN2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SCRN2 data layer compared with 20 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SCRN2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SCRN2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and LSCC are the cancer types where SCRN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.880	0.431	.002	35	view →
LUAD	DFS	Tertile	All	1.000	0.615	.005	12	view →
LSCC	DFS	Tertile	II,III,IV	0.885	1.000	.027	6	view →
PDAC	OS	Median	II,III,IV	0.783	0.925	.021	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SCRN2–CCRCC (DFS)

Open the CCRCC breakdown →